Clinical Trial Update: An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of Afatinib (BIBW 2992) in advanced non-small cell lung cancer patients previously treated with Erlotinib or Gefitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Sheba Medical Center | Conditions: NSCLC | Phase 2 | Status: UNKNOWN